Hepatitis C in alcohol dependence:drinking versus disulfiram

Area of Science:

• Hepatology
• Addiction Medicine
• Pharmacology

Background:

• Hepatitis C virus (HCV) disproportionately affects individuals with alcohol dependence (AD).
• The use of disulfiram to promote abstinence in HCV + AD patients is debated.
• Continued alcohol consumption accelerates liver damage in HCV-infected individuals.

Purpose of the Study:

• To review the literature on disulfiram's efficacy and safety in treating alcohol dependence in Hepatitis C virus patients.
• To assess the comparative liver toxicity of alcohol versus disulfiram in this population.
• To evaluate the potential benefits of disulfiram in facilitating HCV treatment and long-term abstinence.

Main Methods:

• Literature review of studies concerning Hepatitis C virus (HCV) and alcohol dependence (AD).
• Analysis of data on the effects of alcohol consumption and disulfiram treatment on liver health.
• Evaluation of abstinence-associated outcomes in HCV + AD patients.

Main Results:

• Abstinence in HCV + AD individuals is linked to slower liver disease progression and better antiviral treatment response.
• Disulfiram's risk of liver injury appears significantly lower than the hepatotoxicity of continued alcohol intake.
• Close monitoring during the initial six months of disulfiram therapy is recommended, with adverse effects often reversible upon discontinuation.

Conclusions:

• Disulfiram therapy may be a viable option for achieving prolonged abstinence in HCV + AD patients, enabling successful antiviral treatment.
• Disulfiram can provide a window for behavioral therapies crucial for long-term recovery.
• Further large-scale prospective studies are essential to definitively establish the role of disulfiram in managing HCV and alcohol dependence.